Abstract:Until recently, only symptomatic therapies, in the form of acetylcholine esterase inhibitors and NMDA-receptor antagonists, have been available for the treatment of Alzheimer's disease. However, advancements in our understanding of the amyloid cascade hypothesis have led to a development of disease-modifying therapeutic strategies. These include immunotherapies based on an infusion of monoclonal antibodies against amyloid-β, three of which have been approved for the treatment of Alzheimer's disease in the USA (one of them, lecanemab, has also been approved in several other countries). They all lead to a dramatic reduction of amyloid plaques in the brain, whereas their clinical effects have been more limited. Moreover, they can all lead to side effects in the form of amyloid-related imaging abnormalities. Ongoing developments aim at facilitating their administration, further improving their effects and reducing the risk for amyloid-related imaging abnormalities. Moreover, a number of anti-tau immunotherapies are in clinical trials, but none has so far shown any robust effects on symptoms or pathology. Another line of development is represented by gene therapy. To date, only antisense oligonucleotides against amyloid precursor protein/amyloid-β and tau have reached the clinical trial stage but a variety of gene editing strategies, such as clustered regularly interspaced short palindromic repeats/Cas9-mediated non-homologous end joining, base editing, and prime editing, have all shown promise on preclinical disease models. In addition, a number of other pharmacological compounds targeting a multitude of biochemical processes, believed to be centrally involved in Alzheimer's disease, are currently being evaluated in clinical trials. This article delves into current and future perspectives on the treatment of Alzheimer's disease, with an emphasis on immunotherapeutic and gene therapeutic strategies.

The Molecular Efficacy of CRISPR-Cas9 in TreatingAlzheimer’s Disease

Prevention and Treatment of Alzheimer's Disease Through CRISPR/Cas Technology

Application of CRISPR/Cas9 System in the Treatment of Alzheimer's Disease and Neurodegenerative Diseases

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders

Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice

Tandem peptide lipid CRISPR-Cas9 complex combating APP and APOE4 gene abnormality in Alzheimer's disease

Applying gene‐editing technology to elucidate the functional consequence of genetic and epigenetic variation in Alzheimer’s disease

Advances in Genetic and Molecular Understanding of Alzheimer's Disease

Recent Advances: Decoding Alzheimer’s Disease with Stem Cells

In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease

Precision Gene Editing Strategies with CRISPR-Cas9 for Advancing Cancer Immunotherapy and Alzheimer's Disease

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

CRISPR/Cas9 Mechanism and Applications Progression

Advances with RNA Interference in Alzheimer&rsquo;s Disease Research

CRISPR-Cas9 guided rna based model for the treatment of Amyotrophic Lateral Sclerosis: A progressive neurodegenerative disorder

Molecular Therapeutics in Development to Treat Alzheimer's Disease

Long term rescue of Alzheimer's deficits in vivo by one-time gene-editing of App C-terminus

Insertion of the protective APP A673T mutation by CRISPR/Cas9 base editing or PRIME editing

Long term rescue of Alzheimer deficits in vivo by one-time gene-editing of App C-terminus.